The natural compound Alizarin as an osteotropic drug for the treatment of bone tumors

Journal of Orthopaedic Research

Volumn 30, Issue 9, 2012, Pages 1486-1492

  Fotia, Caterina ^a   Avnet, Sofia ^a   Granchi, Donatella ^a   Baldini, Nicola ^a,b  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

alizarin; anthraquinone; bone tumors; cell cycle; osteotropism

Indexed keywords

ALIZARIN; MITOGEN ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE TUMOR; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT;

ANTHRAQUINONES; BONE MARROW CELLS; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MAP KINASE SIGNALING SYSTEM; OSTEOSARCOMA;

EID: 84863857067     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22101     Document Type: Article

References (40)

1. Savage SA, Mirabello L., 2011. Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma 2011: 548151.
2. Jimenez-Andrade JM, Mantyh WG, Bloom AP, et al. 2010. Bone cancer pain. Ann N Y Acad Sci 1198: 173-181.
3. Aaron AD., 1998. Treatment of metastatic adenocarcinoma of the pelvis and the extremities. J Bone Joint Surg Am 80: 763-764.
4. Costa L, Major PP., 2009. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6: 163-174.
5. Riccio AI, Wodajo FM, Malawer M., 2007. Metastatic carcinoma of the long bones. Am Fam Physician 76: 1489-1494. (Pubitemid 350127887)
6. D'Adamo DR., 2011. Appraising the current role of chemotherapy for the treatment of sarcoma. Semin Oncol 38: 19-29.
7. Harvey HA., 1997. Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma. Cancer 80: 1646-1651. (Pubitemid 27444036)
8. Shelley M, Harrison C, Coles B, et al. 2006. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 4: CD005247.
9. Donnelly JG., 2004. Pharmacogenetics in cancer chemotherapy: balancing toxicity and response. Ther Drug Monit 26: 231-235. (Pubitemid 38501224)
10. Rai S, Paliwal R, Vyas SP., 2011. Doxorubicin encapsulated nanocarriers for targeted delivery to estrogen responsive breast cancer. J Biomed Nanotechnol 7: 121-122.
11. Shapira A, Assaraf YG, Livney YD., 2010. Beta-casein nanovehicles for oral delivery of chemotherapeutic drugs. Nanomedicine 6: 119-126.
12. Salerno M, Cenni E, Fotia C, et al. 2010. Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. Curr Cancer Drug Targets 10: 649-659.
13. Jäger I, Hafner C, Welsch C, et al. 2006. The mutagenic potential of madder root in dyeing processes in the textile industry. Mutat Res 605: 22-29.
14. Barnhart ER., 1987. Physician's Desk Reference, 41st ed. Oradell, NJ: Medical Economics Co.
15. Mori H, Yoshimi N, Iwata H, et al. 1990. Carcinogenicity of naturally occurring 1-hydroxyanthraquinone in rats: Induction of large bowel, liver and stomach neoplasms. Carcinogenesis 11: 799-802. (Pubitemid 20150248)
16. Huang Q, Lu G, Shen HM, et al. 2007. Anti-cancer properties of anthraquinones from rhubarb. Med Res Rev 27: 609-630. (Pubitemid 47282446)
17. Doi AM, Irwin RD, Bucher JR., 2005. Influence of functional group substitutions on the carcinogenicity of anthraquinone in rats and mice: analysis of long-term bioassays by the National Cancer Institute and the National Toxicology Program. J Toxicol Environ Health B Crit Rev 8: 109-126. (Pubitemid 40364846)
18. Ohkuma Y, Hiraku Y, Kawanishi S., 2001. Sequence-specific DNA damage induced by carcinogenic danthron and anthraquinone in the presence of Cu(II), cytochrome P450 reductase and NADPH. Free Radic Res 34: 595-604. (Pubitemid 32694648)
19. Yasui Y, Takeda N., 1983. Identification of a mutagenic substance in Rubia tinctorum L. (madder) root as lucidin. Mutat Res 121: 185-190. (Pubitemid 13005687)
20. Marec F, KollÃrovà I, Yegorov A., 2001. Mutagenicity of natural anthraquinones from Rubia tinctorum in the Drosophila wing spot test. Planta Med 67: 127-131. (Pubitemid 32234674)
21. Takahashi E, Fujita K, kamataki T, et al. 2002. Inhibition of human cytochrome P450 1B1, 1A1 and 1A2 by antigenotoxic compounds, purpurin and alizarin. Mutat Res 508: 147-156.
22. Kamei H, Tatsurou K, Takashi K, et al. 1998. Inhibition of cell growth in culture by quinines. Cancer Biother Radiopharm 13: 185-188. (Pubitemid 28359721)
23. Wölfle D, Schmutte C, Westendorf J, et al. 1990. Hydroxyanthraquinones as tumor promoters: enhancement of malignant transformation of C3H mouse fibroblasts and growth stimulation of primary rat hepatocytes. Cancer Res 50: 6540-6544. (Pubitemid 20348775)
24. Virtanen P, Isotupa K., 1980. Staining properties of alizarin red S for growing bone in vitro. Acta Anat (Basel) 108: 202-207. (Pubitemid 10084876)
25. Koo S, König B, Allegrini S, et al. 2006. Titanium implant osseointegration with calcium pyrophosphate in rabbits. J Biomed Mater Res B Appl Biomater 76: 373-380. (Pubitemid 43165396)
26. Pautke C, Vogt S, Tischer T, et al. 2005. Polychrome labeling of bone with seven different fluorochromes: enhancing fluorochrome discrimination by spectral image analysis. Bone 37: 441-445. (Pubitemid 41317316)
27. Lopes CDE, König C, Júnior B, et al. 2004. Bone remodeling analysis of various dental implant surfaces using polyfluorochrome sequential labeling in rabbit tibias. Ann Anat 186: 331-335.
28. Kayacan R., 2007. The effect of staining on the monotonic tensile mechanical properties of human cortical bone. J Anat 211: 654-661. (Pubitemid 47617323)
29. Ciapetti G, Ambrosio L, Marletta G, et al. 2006. Human bone marrow stromal cells: in vitro expansion and differentiation for bone engineering. Biomaterials 27: 6150-6160. (Pubitemid 44414980)
30. Roberts PJ, Der CJ., 2007. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310. (Pubitemid 46763022)
31. Calvo F, Agudo-Ibáñez L, Crespo P., 2010. The Ras-ERK pathway: understanding site-specific signaling provides hope of new anti-tumor therapies. Bioessays 32: 412-421.
32. Cantley LC., 2002. The phosphoinositide 3-kinase pathway. Science 296: 1655-1657. (Pubitemid 34579158)
33. Bellacosa A, Kumar CC, Di Cristofano A, et al. 2005. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94: 29-86. (Pubitemid 41202364)
34. Susa M, Iyer AK, Ryu K, et al. 2009. Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma. BMC Cancer 16: 9: 399.
35. Hilgert I, Cudlín J, Steinerová N, et al. 1977. Antitumour and immunosuppressive activity of hydroxyanthraquinones and their glucosides. Folia Biol (Praha) 23: 99-109.
36. Pouysségur J, Volmat V, Lenormand P., 2002. Fidelity and spatio-temporal control in MAP kinase (ERKs) signaling. Biochem Pharmacol 64: 755-763. (Pubitemid 35238027)
37. Chen X, Thakkar H, Tyan F, et al. 2001. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20: 6073-6083. (Pubitemid 32955050)
38. Thakkar H, Chen X, Tyan F, et al. 2001. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance. J Biol Chem 276: 38361-38369.
39. Zhou X, Song B, Jin L, et al. 2006. Isolation and inhibitory activity against ERK phosphorylation of hydroxyanthraquinones from rhubarb. Bioorg Med Chem Lett 16: 563-568. (Pubitemid 43014838)
40. Lin SY, Lai WW, Ho CC, et al. 2009. Emodin induces apoptosis of human tongue squamous cancer SCC-4 cells through reactive oxygen species and mitochondria-dependent pathways. Anticancer Res 29: 327-335.